Celldex Therapeutics vs Cervomed
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $1.5m for Celldex Therapeutics (2.6 times as much). Cervomed grew faster (-58.9% against -78.0%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -16748.0%. Celldex Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Celldex TherapeuticsCLDX, 2025 | CervomedCRVO, 2025 |
|---|---|---|
| Revenue | $1.5m | $4.0m |
| Revenue growth | -78.0% | -58.9% |
| Net income | −$259m | −$27.0m |
| Operating margin | -18599.8% | -706.2% |
| Net margin | -16748.0% | -673.1% |
| Return on equity | -40.6% | -93.9% |
| Free cash flow | −$214m | −$23.4m |
| Cash | $28.9m | $8.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 198 | 15 |
| Market value | $2.32bn | $21.0m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 0 buys, 2 sales | 19 buys, 0 sales |